WAVE LIFE SCIENCES LTD. (1U5) - Net Assets
Based on the latest financial reports, WAVE LIFE SCIENCES LTD. (1U5) has net assets worth €518.36 Million EUR (≈ $606.01 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€638.50 Million ≈ $746.47 Million USD) and total liabilities (€120.14 Million ≈ $140.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read WAVE LIFE SCIENCES LTD. (1U5) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €518.36 Million |
| % of Total Assets | 81.18% |
| Annual Growth Rate | 99.84% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 273.6 |
WAVE LIFE SCIENCES LTD. - Net Assets Trend (2021–2025)
This chart illustrates how WAVE LIFE SCIENCES LTD.'s net assets have evolved over time, based on quarterly financial data. Also explore total assets of WAVE LIFE SCIENCES LTD. for the complete picture of this company's asset base.
Annual Net Assets for WAVE LIFE SCIENCES LTD. (2021–2025)
The table below shows the annual net assets of WAVE LIFE SCIENCES LTD. from 2021 to 2025. For live valuation and market cap data, see how much is WAVE LIFE SCIENCES LTD. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €518.36 Million ≈ $606.01 Million |
+147.41% |
| 2024-12-31 | €209.51 Million ≈ $244.95 Million |
+428.68% |
| 2023-12-31 | €39.63 Million ≈ $46.33 Million |
+187.89% |
| 2022-12-31 | €-45.09 Million ≈ $-52.72 Million |
-238.75% |
| 2021-12-31 | €32.50 Million ≈ $37.99 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to WAVE LIFE SCIENCES LTD.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52072200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.84 Billion | 355.85% |
| Total Equity | €518.36 Million | 100.00% |
WAVE LIFE SCIENCES LTD. Competitors by Market Cap
The table below lists competitors of WAVE LIFE SCIENCES LTD. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vedant Fashions Limited
NSE:MANYAVAR
|
$1.12 Billion |
|
PROS Holdings Inc
NYSE:PRO
|
$1.12 Billion |
|
Railtel Corporation Of India Limited
NSE:RAILTEL
|
$1.12 Billion |
|
CWB Automotive Electronics Co Ltd
SHG:605005
|
$1.12 Billion |
|
SILEX Systems Ltd
AU:SLX
|
$1.12 Billion |
|
VIEL & Cie société anonyme
PA:VIL
|
$1.12 Billion |
|
Center International Group Co Ltd
SHG:603098
|
$1.12 Billion |
|
Xinjiang Baodi Mining Co. Ltd. A
SHG:601121
|
$1.12 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in WAVE LIFE SCIENCES LTD.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 209,515,000 to 518,357,000, a change of 308,842,000 (147.4%).
- Net loss of 204,378,000 reduced equity.
- New share issuances of 472,486,000 increased equity.
- Other factors increased equity by 40,734,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-204.38 Million | -39.43% |
| Share Issuances | €472.49 Million | +91.15% |
| Other Changes | €40.73 Million | +7.86% |
| Total Change | €- | 147.41% |
Book Value vs Market Value Analysis
This analysis compares WAVE LIFE SCIENCES LTD.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.50x to 2.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.54 | €5.70 | x |
| 2022-12-31 | €-0.52 | €5.70 | x |
| 2023-12-31 | €0.33 | €5.70 | x |
| 2024-12-31 | €1.37 | €5.70 | x |
| 2025-12-31 | €2.76 | €5.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently WAVE LIFE SCIENCES LTD. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -39.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -478.33%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.23x
- Recent ROE (-39.43%) is above the historical average (-121.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -376.16% | -298.42% | 0.20x | 6.37x | €-125.49 Million |
| 2022 | 0.00% | -4434.72% | 0.02x | 0.00x | €-157.31 Million |
| 2023 | -145.12% | -50.76% | 0.41x | 6.94x | €-61.48 Million |
| 2024 | -46.30% | -89.57% | 0.31x | 1.68x | €-117.96 Million |
| 2025 | -39.43% | -478.33% | 0.07x | 1.23x | €-256.21 Million |
Industry Comparison
This section compares WAVE LIFE SCIENCES LTD.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $772,487,259
- Average return on equity (ROE) among peers: -28.35%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| WAVE LIFE SCIENCES LTD. (1U5) | €518.36 Million | -376.16% | 0.23x | $1.12 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About WAVE LIFE SCIENCES LTD.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more